000756 新华制药
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入4,638,804-1.98%8,466,3108,100,8457,502,9876,560,078
减:营业总成本4,343,478-1.60%7,940,3087,530,9057,020,4786,173,736
    其中:营业成本3,709,2654.55%6,424,7615,709,1425,465,6564,786,410
               财务费用9,878510.54%12,14116,35132,01952,903
               资产减值损失(50,288)4.09%(51,614)(69,283)(43,526)(33,267)
公允价值变动收益------------
投资收益5,879-38.22%9,8369,5838,3658,017
    其中:对联营企业和合营企业的投资收益(1,140)-185.44%1581,418447(1,089)
营业利润264,247-14.09%534,371534,582476,707425,591
利润总额263,527-13.13%533,653532,686471,774421,233
减:所得税费用32,3595.76%46,93926,57945,66559,159
净利润231,168-15.25%486,715506,107426,110362,074
减:非控股权益7,4120.68%16,6919,59515,04713,526
股东净利润223,757-15.69%470,024496,512411,063348,548

市场价值指针
每股收益 (元) *0.320-17.95%0.6900.7400.6200.560
每股派息 (元) *----0.2750.2500.2000.150
每股净资产 (元) *7.4326.69%7.3156.7496.1625.528
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容